Patents Assigned to CHU NANTES
-
Patent number: 11932638Abstract: The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R? is an -A1-Cy1 group, or R is an -A1-Cy1 group and R? is an R1 group, R1 particularly being H or (C1-C6)alkyl group; A1 being an —NH— radical or —NH—CH2— radical; Cy1 particularly being a phenyl group, A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.Type: GrantFiled: May 23, 2018Date of Patent: March 19, 2024Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE, UNIVERSITE D'ORLEANS, UNIVERSITE DE TOURS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE SCIENTIFIQUE (INSERM), CHU NANTESInventors: Sylvain Routier, Frédéric Buron, Nuno Rodrigues, Gaëlle Fourriere-Grandclaude, Christophe Vandier, Aurélie Chantome, Marie Potier-Cartereau, Maxime Gueguinou, Séverine Marionneau-Lambot
-
Patent number: 11795144Abstract: The present invention concerns a compound having the following formula (I): wherein: A is in particular —N(R?a)—C(?O)—R, R?a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): X is in particular chosen from the group consisting of: —SO2—N(R?b)—, R?b being H or a (C1-C6)alkyl group, —N(R?b)—SO2—, R?b being H or a (C1-C6)alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of cancers, such as metastatic cancers.Type: GrantFiled: June 6, 2018Date of Patent: October 24, 2023Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, CHU NANTESInventors: Vincent Sauzeau, Gervaise Loirand, Jacques Lebreton, Arnaud Tessier, Agnès Quemener
-
Patent number: 11761960Abstract: The present invention relates to an in vitro method for determining the risk of occurrence of chronic lung graft dysfunction in a human subject comprising: a) measuring the level of CD9+ B cells in a blood sample of the subject, b) comparing the level of CD9+ B cells measured at step a) with one or more reference values of the level of CD9+ B cells, and c) determining the risk of occurrence of chronic lung graft dysfunction in the said subject from the comparison performed at step b).Type: GrantFiled: April 27, 2018Date of Patent: September 19, 2023Assignees: UNIVERSITE DE NANTES, INSTITUT NATIONALE DE LE SANTE ET DE LA RECHERCHE MEDICALE, CHU NANTESInventors: Carole Brosseau, Maxim Durand, Antoine Magnan, Sophie Brouard
-
Patent number: 11607419Abstract: The present invention concerns a compound having the following formula (I): wherein: —A is in particular —N(R?a)—C(?O)—R, R?a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): —X is in particular chosen from the group consisting of: —SO2—N(R?b)—, R?b being H or a (C1-C6)alkyl group, —N(R?b)—SO2—, R?b being H or a (C1-C6)alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma.Type: GrantFiled: June 6, 2018Date of Patent: March 21, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, CHU NANTESInventors: Vincent Sauzeau, Gervaise Loirand, Jacques Lebreton, Arnaud Tessier, Agnes Quemenier
-
Patent number: 11351201Abstract: The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1:1 or 7:3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer).Type: GrantFiled: December 12, 2013Date of Patent: June 7, 2022Assignees: Universite De Nantes, Chu NantesInventors: Brigitte Dreno, Thomas Zuliani, Soraya Saiagh
-
Patent number: 11203740Abstract: The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising performing a depth filtration of a starting material previously obtained from cells producing rAAV particles comprising a cell lysate and/or a culture supernatant, followed by a first step of anion-exchange chromatography, a second step of anion-exchange chromatography and a final step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.Type: GrantFiled: February 9, 2016Date of Patent: December 21, 2021Assignees: INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CHU NANTES, ASSOCIATION FRANCAISE CONTRE LES MYOPATHIESInventor: Nicole Brument
-
Patent number: 11021689Abstract: The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to an affinity purification step, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to: c1) a step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a salt gradient, preferably a linear salt gradient, and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; or c2) a step of density gradient centrifugation, wherein the rAAV-containing fraction is collected, whereby a second rAAV eType: GrantFiled: February 9, 2016Date of Patent: June 1, 2021Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTER, CHU NANTES, ASSOCIATION FRANCAISE CONTRE LES MYOPATHIESInventor: Nicole Brument
-
Patent number: 10703813Abstract: The present disclosure relates to novel anti IL-34 antibodies or antigen-binding fragments thereof specifically binding cytokine IL-34 with high affinity, the method of obtaining of these antibodies and their therapeutic use.Type: GrantFiled: December 21, 2015Date of Patent: July 7, 2020Assignees: UNIVERSITE DE NANTES, CHU NANTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Dominique Heymann, Aude Segaliny, Régis Brion
-
Patent number: 10632154Abstract: The present invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si-HPMC) for the treatment of type 1 diabetes. Methods and kits are also provided for restoring and/or maintaining euglycemia in type 1 diabetic patients and in type 1 prediabetic patients.Type: GrantFiled: November 10, 2016Date of Patent: April 28, 2020Assignees: Ecole Nationale Veterinaire, Chu Nantes, Universite de Nantes, Institute National de la Sante et de la Recherche MedicaleInventors: Jean-Marie Bach, Mathilde Mosser, Apolline Salama, Anne Moure, Xavier Leveque, Pierre Weiss, Jérôme Guicheux, Cécile Boyer, David Riochet
-
Publication number: 20180221493Abstract: The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.Type: ApplicationFiled: April 10, 2018Publication date: August 9, 2018Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes, CHU NantesInventors: Pierre Weiss, Eva Mathieu, Jerome Guicheux, Patricia Lemarchand
-
Publication number: 20180187150Abstract: The invention relates to a method for the cryopreservation of at least one sample of tumour-infiltrating lymphocytes, comprising the following steps: i) the in vitro culture of tumour-infiltrating lymphocytes using a collection of samples of in-transit skin nodules, ganglion or metastasis, from a patient with a stage III or IV melanoma, said step comprising the emergence of the tumour-infiltrating lymphocytes contained in the sample of in-transit skin nodules, ganglion or metastasis, followed by the stimulation of the tumour-infiltrating lymphocytes resulting from the emergence step, and, subsequently, the amplification of the stimulated tumour infiltrating lymphocytes; ii) the mixing of at least one sample obtained in step (i) with a composition comprising, in a physiologically acceptable medium, a) human albumin serum, b) at least one saccharide, and c) at least two ingredients selected from among DMSO, L-cysteine, coenzyme Q10 and C3-C5 alkanediols; and subsequently iii) the freezing of the mixture obtaineType: ApplicationFiled: June 30, 2016Publication date: July 5, 2018Applicant: Chu NantesInventor: Joffrey De Larichaudy
-
Patent number: 9968681Abstract: The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.Type: GrantFiled: June 4, 2012Date of Patent: May 15, 2018Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes, CHU NantesInventors: Pierre Weiss, Eva Mathieu, Jérôme Guicheux, Patricia Lemarchand
-
Publication number: 20170342148Abstract: The present disclosure relates to novel anti IL-34 antibodies or antigen-binding fragments thereof specifically binding cytokine IL-34 with high affinity, the method of obtaining of these antibodies and their therapeutic use.Type: ApplicationFiled: December 21, 2015Publication date: November 30, 2017Applicants: Universite de Nantes, Chu Nantes, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Dominique Heymann, Aude Segaliny, Régis Brion
-
Patent number: 9724144Abstract: A bone regeneration membrane comprising: a dense layer made of resorbable polymer, said dense layer having first and second opposite surfaces and being adapted to form a barrier to cells and soft tissues, a nanofibrillar layer made of resorbable polymer and attached to the first surface of the dense layer, said nanofibrillar layer comprising fibers having a diameter of nanometer size, said fibers being interlaced so as to present an average pore size greater than 10 ?m to allow cell permeability and bone tissue regeneration, the nanofibrillar layer having a permeability ? between 0.4*10-9 m2 and 11*10-9 m2, preferably between 1*10-9 m2 and 4*10-9 m2, in particular substantially of 2*10-9 m2.Type: GrantFiled: July 8, 2011Date of Patent: August 8, 2017Assignees: UNIVERSITE DE NANTES, CHU NANTESInventors: Alain Hoornaert, Pierre Layrolle, Jerome Sohier
-
Patent number: 9290421Abstract: The present invention relates to a compound having formula (I): wherein: —X is in particular 125I Or 211At; —R1 and R?1 are independently from each other chosen preferably from the group consisting of electron-withdrawing groups and alkyl groups; —R2 is chosen from the group consisting of: H, alkyl groups, functional groups being able to bind a vector, and functional groups having targeting properties which make the compound of the invention a vector itself; —Z is a heteroatom, R5, R8 and R9 are preferably H; —Y is preferably an electron withdrawing group.Type: GrantFiled: February 2, 2011Date of Patent: March 22, 2016Assignees: Institut National de la Santé de la Recherche Medicalé, Université de Nantes, CHU NantesInventors: Jean-Francois Gestin, Francois Guerard, Alain Faivre-Chauvet
-
Patent number: 9285360Abstract: The invention concerns: —a silylated biomolecule having the following formula (I): —the process for the preparation of a silylated biomolecule of formula (I), —the use of a silylated biomolecule of formula (I) to functionalize the surface of a support, —a process for the preparation of a hydrogel by use of a silylated biomolecule of formula (I), the hydrogel obtainable by said process, —said hydrogel as a biological tissue substitute, —a composition comprising said hydrogel in a pharmaceutically acceptable vehicle, —said composition for the release of active principle.Type: GrantFiled: January 25, 2011Date of Patent: March 15, 2016Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes, CHU Nantes, Institut Francais de Recherche pour l'Exploitation De la Mer—IFREMERInventors: Pierre Weiss, Jerome Guicheux, Gildas Rethore, Emile Rederstorff, Samia Laib
-
Publication number: 20150320804Abstract: The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1:1 or 7:3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer).Type: ApplicationFiled: December 12, 2013Publication date: November 12, 2015Applicants: CHU NANTES, UNIVERSITE DE NANTESInventors: Brigitte Dreno, Thomas Zuliani, Soraya Saiagh
-
Publication number: 20150139901Abstract: The present invention concerns radioactive rhodium complexes, their preparation methods, and their use for the radiolabelling of biomolecules, especially monoclonal antibodies.Type: ApplicationFiled: May 14, 2013Publication date: May 21, 2015Applicants: Institut National de la Sante et de la Recherche (INSERM), Chu Nantes, Universite de Nantes, Centre National de la Recherche Scientifique (C.N.R.S.), Universite d' AngersInventors: Alain Faivre-Chauvet, Holisoa Rajaerison, Jean-Francois Gestin
-
Patent number: 8975371Abstract: The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.Type: GrantFiled: November 21, 2013Date of Patent: March 10, 2015Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Nantes, Chu NantesInventors: Nathalie Labarriere, Agnes Moreau-Aubry, Yann Godet
-
Publication number: 20150037837Abstract: The present invention relates to an in vitro method for diagnosing the infectious state of an individual on the basis of a sample of white corpuscles arising from a biological specimen taken from an organ potentially infected by a pathogenic micro-organism of said individual, comprising at least the following two steps: i) measuring the mean cellular intensity of the autofluorescence of said sample, and ii) comparing the intensity measured in step i) with a control value, so as to determine the infectious state of said individual. The diagnostic method of the invention uses a routine optical material making it possible to work in wavelength regions which are compatible with the cellular autofluorescence, and thus constitutes a rapid, reliable and inexpensive aid for the diagnosis or monitoring of an infection in an individual.Type: ApplicationFiled: March 22, 2012Publication date: February 5, 2015Applicants: UNIVERSITE DE NANTES, CHU NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SUD 11Inventors: Karim Asehnoune, Marie-Pierre Fontaine-Aupart, Sandrine Lecart, Antoine Monsel, Antoine Roquilly